Institutional ownership of Tevogen’s common stock increased by 24% in the second quarter of 2025 compared to the first quarter. The largest contributors to this growth were Morgan Stanley and BlackRock, who together increased their holdings by 80%. The number of institutional holders also rose from 51 to 55, with 72% increasing or maintaining their positions. Tevogen’s Head of Investor Relations, Tapan Shah, stated that this increase reflects long-term investor confidence in the company’s scientific and operational progress, including positive clinical data and advancements in GMP cell manufacturing capabilities.

This press release also contains forward-looking statements regarding Tevogen’s research and manufacturing plans, growth expectations, and product development for infectious diseases and cancer. Factors that could impact the company’s performance include the need for additional capital, changes in market conditions, economic factors, and regulatory challenges. Tevogen emphasizes that these statements are based on management’s expectations and are subject to various risks and uncertainties. Investors are advised not to rely solely on forward-looking statements, as actual results may differ from expectations.

Read more at GlobeNewswire: Tevogen Sees Continued Growth in Institutional Ownership in